Candice D. Church

Candice D. Church

Auto-generated profile, based on publicly available information

Candice D. Church

Department of Dermatology, University of Washington, Seattle, Washington

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
VKVandana Kalia
Vandana Kalia
YYYevgeniy Yuzefpolskiy
Yevgeniy Yuzefpolskiy
AVAdithya Vegaraju
Adithya Vegaraju
HXHanxi Xiao
Hanxi Xiao
FBFlorian Baumann
Florian Baumann
SSSurojit Sarkar
Surojit Sarkar
PD-1 signals promote development of long-lived quiescent memory CD8 T cells by regulating the balance of glycolysis and fatty acid oxidation.

27 March 2020 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
STShira Tabachnick‐Cherny
Shira Tabachnick‐Cherny
TPThomas Pulliam
Thomas Pulliam
CCCandice Church
Candice Church
DKDavid M Koelle
David M Koelle
PNPeter P. Nghiem
Peter P. Nghiem

1 May 2020 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
LJLichen Jing
Lichen Jing
MOMariliis Ott
Mariliis Ott
CCCandice D. Church
Candice D. Church
RKRima M. Kulikauskas
Rima M. Kulikauskas
DIDafina Ibrani
Dafina Ibrani
DKDavid M Koelle
David M Koelle
Merkel cell carcinoma (MCC) is often caused by persistent expression of Merkel cell polyomavirus (MCPyV) T-antigen (T-Ag). These non-self proteins comprise about 400 amino acids (AA). Clinical responses to immune checkpoint inhibitors, seen in about half of patients, may relate to T-Ag–specific T cells. Strategies to increase CD8+ T-cell number, breadth, or function could augment checkpoint inhibition, but vaccines to augment immunity must avoid delivery of oncogenic T-antigen domains. We probed MCC tumor-infiltrating lymphocytes (TIL) with an artificial antigen-presenting cell (aAPC) system and confirmed T-Ag recognition with synthetic peptides, HLA-peptide tetramers, and dendritic cells (DC). TILs from 9 of 12 (75%) subjects contained CD8+ T cells recognizing 1–8 MCPyV epitopes per person. Analysis of 16 MCPyV CD8+ TIL epitopes and prior TIL data indicated that 97% of patients with MCPyV+ MCC had HLA alleles with the genetic potential that restrict CD8+ T-cell responses to MCPyV T-Ag. The LT AA 70–110 region was epitope rich, whereas the oncogenic domains of T-Ag were not commonly recognized. Specific recognition of T-Ag–expressing DCs was documented. Recovery of MCPyV oncoprotein–specific CD8+ TILs from most tumors indicated that antigen indifference was unlikely to be a major cause of checkpoint inhibition failure. The myriad of epitopes restricted by diverse HLA alleles indicates that vaccination can be a rational component of immunotherapy if tumor immune suppression can be overcome, and the oncogenic regions of T-Ag can be modified without impacting immunogenicity.

27 November 2018 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
NMNatalie J. Miller
Natalie J. Miller
CCCandice D. Church
Candice D. Church
SFSteven P. Fling
Steven P. Fling
RKRima Kulikauskas
Rima Kulikauskas
NRNirasha Ramchurren
Nirasha Ramchurren
PNPeter P. Nghiem
Peter P. Nghiem
Background Merkel cell carcinoma (MCC) is an aggressive skin cancer that frequently responds to anti-PD-1 therapy. MCC is associated with sun exposure and, in 80% of cases, Merkel cell polyomavirus (MCPyV). MCPyV-specific T and B cell responses provide a unique opportunity to study cancer-specific immunity throughout PD-1 blockade therapy. Methods Immune responses were assessed in patients (n = 26) with advanced MCC receiving pembrolizumab. Peripheral blood mononuclear cells (PBMC) were collected at baseline and throughout treatment. MCPyV-oncoprotein antibodies were quantified and T cells were assessed for MCPyV-specificity via tetramer staining and/or cytokine secretion. Pre-treatment tumor biopsies were analyzed for T cell receptor clonality. Results MCPyV oncoprotein antibodies were detectable in 15 of 17 (88%) of virus-positive MCC (VP-MCC) patients. Antibodies decreased in 10 of 11 (91%) patients with responding tumors. Virus-specific T cells decreased over time in patients who had a complete response, and increased in patients who had persistent disease. Tumors that were MCPyV(+) had a strikingly more clonal (less diverse) intratumoral TCR repertoire than virus-negative tumors (p = 0.0001). Conclusions Cancer-specific T and B cell responses generally track with disease burden during PD-1 blockade, in proportion to presence of antigen. Intratumoral TCR clonality was significantly greater in VP-MCC than VN-MCC tumors, suggesting expansion of a limited number of dominant clones in response to fewer immunogenic MCPyV antigens. In contrast, VN-MCC tumors had lower clonality, suggesting a diverse T cell response to numerous neoantigens. These findings reveal differences in tumor-specific immunity for VP-MCC and VN-MCC, both of which often respond to anti-PD-1 therapy.

27 October 2021 in Patterns
Verified
Journal Article
Open access
EGEvan Greene
Evan Greene
GFGreg Finak
Greg Finak
LDLeonard A. D'AMico
Leonard A. D'AMico
NBNina Bhardwaj
Nina Bhardwaj
CCCandice D. Church
Candice D. Church
RGRaphael Gottardo
Raphael Gottardo
We introduce a new method for single-cell cytometry studies, FAUST, which performs unbiased cell population discovery and annotation. FAUST processes experimental data on a per-sample basis and returns biologically interpretable cell phenotypes, making it well suited for the analysis of complex datasets. We provide simulation studies that compare FAUST with existing methodology, exemplifying its strength. We apply FAUST to data from a Merkel cell carcinoma anti-PD-1 trial and discover pre-treatment effector memory T cell correlates of outcome co-expressing PD-1, HLA-DR, and CD28. Using FAUST, we then validate these correlates in cryopreserved peripheral blood mononuclear cell samples from the same study, as well as an independent CyTOF dataset from a published metastatic melanoma trial. Finally, we show how FAUST's phenotypes can be used to perform cross-study data integration in the presence of diverse staining panels. Together, these results establish FAUST as a powerful new approach for unbiased discovery in single-cell cytometry.

30 January 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
UHUlla Kring Hansen
Ulla Kring Hansen
CCCandice D. Church
Candice D. Church
ASAna Micaela Carnaz Simões
Ana Micaela Carnaz Simões
MFMarcus Svensson Frej
Marcus Svensson Frej
ABAmalie Kai Bentzen
Amalie Kai Bentzen
SHSine Reker Hadrup
Sine Reker Hadrup
Merkel cell carcinoma (MCC) is a highly immunogenic skin cancer primarily induced by Merkel cell polyomavirus, which is driven by the expression of the oncogenic T antigens (T-Ags). Blockade of the programmed cell death protein-1 (PD-1) pathway has shown remarkable response rates, but evidence for therapy-associated T-Ag–specific immune response and therapeutic strategies for the nonresponding fraction are both limited. We tracked T-Ag–reactive CD8 + T cells in peripheral blood of 26 MCC patients under anti-PD1 therapy, using DNA-barcoded pMHC multimers, displaying all peptides from the predicted HLA ligandome of the oncoproteins, covering 33 class I haplotypes. We observed a broad T cell recognition of T-Ags, including identification of 20 T-Ag–derived epitopes we believe to be novel. Broadening of the T-Ag recognition profile and increased T cell frequencies during therapy were strongly associated with clinical response and prolonged progression-free survival. T-Ag–specific T cells could be further boosted and expanded directly from peripheral blood using artificial antigen-presenting scaffolds, even in patients with no detectable T-Ag–specific T cells. These T cells provided strong tumor-rejection capacity while retaining a favorable phenotype for adoptive cell transfer. These findings demonstrate that T-Ag–specific T cells are associated with the clinical outcome to PD-1 blockade and that Ag-presenting scaffolds can be used to boost such responses.